Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score assesses a company's future growth potential based on earnings and sales [4] - Momentum Score tracks price trends to capitalize on upward or downward movements [5] - VGM Score combines all three styles to provide a comprehensive evaluation of stocks [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to identify strong investment opportunities [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [9] Stock Highlight: Krystal Biotech, Inc. (KRYS) - Krystal Biotech is a biotechnology company focused on genetic medicines for unmet medical needs [11] - KRYS holds a Zacks Rank of 2 (Buy) and a VGM Score of B, with a Momentum Style Score of A [11] - The stock has increased by 21.4% in the past four weeks, indicating strong momentum [11] - Recent upward revisions in earnings estimates for fiscal 2025 have raised the consensus estimate to $6.64 per share, reflecting a positive outlook [12]